Abnormalities in chemokine levels in schizophrenia and their clinical correlates

Schizophrenia Research

Volumn 181, Issue , 2017, Pages 63-69

  Hong, Suzi ^a,b   Lee, Ellen E ^a   Martin, Averria Sirkin ^a,c   Soontornniyomkij, Benchawanna ^a   Soontornniyomkij, Virawudh ^a   Achim, Cristian L ^a   Reuter, Chase ^a,c   Irwin, Michael R ^d   Eyler, Lisa T ^a,e   Jeste, Dilip V ^a,c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California San Diego School of Medicine   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Chemokines; Immune system; Inflammation; Schizophrenia

Indexed keywords

CHEMOKINE; EOTAXIN; EOTAXIN 3; FRACTALKINE; INTERLEUKIN 10; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; THYMUS AND ACTIVATION REGULATED CHEMOKINE; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHEMOKINE INDEX; CONTROLLED STUDY; CORRELATIONAL STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RACE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIA ASSESSMENT; SEX; SMOKING; SYMPTOM; AGING; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; IMMUNOASSAY; IMMUNOLOGY; MIDDLE AGED; PSYCHOSIS; SEXUAL CHARACTERISTICS; STATISTICAL MODEL;

ADULT; AGED; AGING; BIOMARKERS; CHEMOKINES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 84994539361     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.09.019     Document Type: Article

References (71)

1. Andreasen, N.C., Scale for the Assessment of Negative Symptoms (SANS). 1983, University of Iowa, Iowa City, IA.
2. Andreasen, N.C., Scale for the Assessment of Positive Symptoms (SAPS). 1984, University of Iowa, Iowa City, IA.
3. Asevedo, E., Gadelha, A., Noto, C., Mansur, R.B., Zugman, A., Belangero, S.I., Berberian, A.A., Scarpato, B.S., Leclerc, E., Teixeira, A.L., Gama, C.S., Bressan, R.A., Brietzke, E., Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J. Psychiatr. Res. 47:10 (2013), 1376–1382.
4. Balashov, K.E., Rottman, J.B., Weiner, H.L., Hancock, W.W., CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96:12 (1999), 6873–6878.
5. Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-Year Population-Based Register Study. 2014.
6. Benros, M.E., Pedersen, M.G., Rasmussen, H., Eaton, W.W., Nordentoft, M., Mortensen, P.B., A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am. J. Psychiatr. 171:2 (2014), 218–226.
7. Beumer, W., Drexhage, R.C., De Wit, H., Versnel, M.A., Drexhage, H.A., Cohen, D., Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37:12 (2012), 1901–1911.
8. Brambilla, P., Bellani, M., Isola, M., Bergami, A., Marinelli, V., Dusi, N., Rambaldelli, G., Tansella, M., Finardi, A.M., Martino, G., Perlini, C., Furlan, R., Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl. Psychiatry, 4, 2014, e406.
9. Brown, S., Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 171:6 (1997), 502–508.
10. Carroll, J.E., Seeman, T.E., Olmstead, R., Melendez, G., Sadakane, R., Bootzin, R., Nicassio, P., Irwin, M.R., Improved sleep quality in older adults with insomnia reduces biomarkers of disease risk: pilot results from a randomized controlled comparative efficacy trial. Psychoneuroendocrinology 55 (2015), 184–192.
11. Delis, D., Kaplan, E., Kramer, J., Delis-Kaplan Executive Function Scale (D-KEFS): Examiner's Manual. 2001, The Psychological Corporation, San Antonio, TX.
12. Dennison, U., McKernan, D., Cryan, J., Dinan, T., Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol. Med. 42:09 (2012), 1865–1871.
13. Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K.J., Janiri, L., Murray, R.M., Dazzan, P., Pariante, C.M., Mondelli, V., Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 31 (2013), 90–95.
14. Dickerson, F., Stallings, C., Origoni, A., Schroeder, J., Katsafanas, E., Schweinfurth, L., Savage, C., Khushalani, S., Yolken, R., Inflammatory markers in recent onset psychosis and chronic schizophrenia. Schizophr. Bull. 42:1 (2016), 134–141.
15. Dimitrov, D.H., Lee, S., Yantis, J., Valdez, C., Paredes, R.M., Braida, N., Velligan, D., Walss-Bass, C., Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr. Res. 151:1–3 (2013), 29–35.
16. Domenici, E., Wille, D.R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., Brittain, C., Rujescu, D., Giegling, I., Turck, C.W., Holsboer, F., Bullmore, E.T., Middleton, L., Merlo-Pich, E., Alexander, R.C., Muglia, P., Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One, 5(2), 2010, e9166.
17. Erbagci, A.B., Herken, H., Koyluoglu, O., Yilmaz, N., Tarakcioglu, M., Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediat. Inflamm. 10:3 (2001), 109–115.
18. Eyre, H.A., Air, T., Pradhan, A., Johnston, J., Lavretsky, H., Stuart, M.J., Baune, B.T., A meta-analysis of chemokines in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 68 (2016), 1–8.
19. First, M., Spitzer, R.L., Gibbon, M., Williams, J.B., Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/PW/PSY SCREEN) New York: Biometrics Research, New York State Psychiatric Institute; 2002. 2002, Biometrics Research, New York State Psychiatric Institute, New York.
20. Foxman, E.F., Campbell, J.J., Butcher, E.C., Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. 139:5 (1997), 1349–1360.
21. Fucetola, R., Seidman, L.J., Kremen, W.S., Faraone, S.V., Goldstein, J.M., Tsuang, M.T., Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol. Psychiatry 48:2 (2000), 137–146.
22. Goff, D.C., Sullivan, L.M., McEvoy, J.P., Meyer, J.M., Nasrallah, H.A., Daumit, G.L., Lamberti, S., D'Agostino, R.B., Stroup, T.S., Davis, S., A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 80:1 (2005), 45–53.
23. Inskip, H.M., Harris, E.C., Barraclough, B., Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br. J. Psychiatry 172:1 (1998), 35–37.
24. Jin, H., Folsom, D., Sasaki, A., Mudaliar, S., Henry, R., Torres, M., Golshan, S., Glorioso, D.K., Jeste, D., Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr. Res. 125:2–3 (2011), 295–299.
25. Joseph, J., Depp, C., Martin, A.S., Daly, R.E., Glorioso, D.K., Palmer, B.W., Jeste, D.V., Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr. Res. 168:1–2 (2015), 456–460.
26. Kaminska, T., Wysocka, A., Marmurowska-Michalowska, H., Dubas-Slemp, H., Kandefer-Szerszen, M., Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. 49:6 (2001), 439–445.
27. Keller, W.R., Kum, L.M., Wehring, H.J., Koola, M.M., Buchanan, R.W., Kelly, D.L., A review of anti-inflammatory agents for symptoms of schizophrenia. J. Psychopharmacol. 27:4 (2013), 337–342.
28. Kipnis, J., Derecki, N.C., Yang, C., Scrable, H., Immunity and cognition: what do age-related dementia, HIV-dementia and ‘chemo-brain’ have in common?. Trends Immunol. 29:10 (2008), 455–463.
29. Kirkpatrick, B., Messias, E., Harvey, P.D., Fernandez-Egea, E., Bowie, C.R., Is schizophrenia a syndrome of accelerated aging?. Schizophr. Bull. 34:6 (2008), 1024–1032.
30. Kraemer, H.C., Kupfer, D.J., Size of treatment effects and their importance to clinical research and practice. Biol. Psychiatry 59:11 (2006), 990–996.
31. Krause, D., Matz, J., Weidinger, E., Wagner, J., Wildenauer, A., Obermeier, M., Riedel, M., Muller, N., The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 11:5 (2010), 739–743.
32. Kroenke, K., Spitzer, R.L., The PHQ-9: a new depression diagnostic and severity measure. Psychiatr. Ann. 32:9 (2002), 509–515.
33. Lin, A., Kenis, G., Bignotti, S., Tura, G.-J.-B., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpe, S., Maes, M., The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32:1 (1998), 9–15.
34. Maes, M., Bosmans, E., Calabrese, J., Smith, R., Meltzer, H.Y., Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:2 (1995), 141–152.
35. Maes, M., Bocchio Chiavetto, L., Bignotti, S., Battisa Tura, G.J., Pioli, R., Boin, F., Kenis, G., Bosmans, E., de Jongh, R., Altamura, C.A., Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 54:3 (2002), 281–291.
36. Mantovani, A., Gray, P.A., Van Damme, J., Sozzani, S., Macrophage-derived chemokine (MDC). J. Leukoc. Biol. 68:3 (2000), 400–404.
37. Martinez-Cengotitabengoa, M., Mac-Dowell, K.S., Leza, J.C., Mico, J.A., Fernandez, M., Echevarria, E., Sanjuan, J., Elorza, J., Gonzalez-Pinto, A., Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr. Res. 137:1–3 (2012), 66–72.
38. Meyer, J.M., McEvoy, J.P., Davis, V.G., Goff, D.C., Nasrallah, H.A., Davis, S.M., Hsiao, J.K., Swartz, M.S., Stroup, T.S., Lieberman, J.A., Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol. Psychiatry 66:11 (2009), 1013–1022.
39. Mondelli, V., Ciufolini, S., Belvederi Murri, M., Bonaccorso, S., Di Forti, M., Giordano, A., Marques, T.R., Zunszain, P.A., Morgan, C., Murray, R.M., Pariante, C.M., Dazzan, P., Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 41:5 (2015), 1162–1170.
40. Murphy, P.M., Baggiolini, M., Charo, I.F., Hebert, C.A., Horuk, R., Matsushima, K., Miller, L.H., Oppenheim, J.J., Power, C.A., International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:1 (2000), 145–176.
41. Murphy, P.M., Baggiolini, M., Charo, I.F., Hébert, C.A., Horuk, R., Matsushima, K., Miller, L.H., Oppenheim, J.J., Power, C.A., International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:1 (2000), 145–176.
42. Naudin, J., Mege, J., Azorin, J., Dassa, D., Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:3 (1996), 269–273.
43. Nikkila, H.V., Ahokas, A., Wahlbeck, K., Rimon, R., Andersson, L.C., Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation. Neuropsychobiology 46:4 (2002), 169–172.
44. Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J.M., Correll, C.U., Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr. Bull. 39:6 (2013), 1230–1241.
45. O'Brien, S.M., Scully, P., Dinan, T.G., Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 160:3 (2008), 256–262.
46. Panizzutti, B., Gubert, C., Schuh, A.L., Ferrari, P., Bristot, G., Fries, G.R., Massuda, R., Walz, J., Rocha, N.P., Berk, M., Teixeira, A.L., Gama, C.S., Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: an accelerated aging biomarker?. J. Affect. Disord. 182 (2015), 64–69.
47. Parmelee, P.A., Thuras, P.D., Katz, I.R., Lawton, M.P., Validation of the cumulative illness rating scale in a geriatric residential population. J. Am. Geriatr. Soc. 43:2 (1995), 130–137.
48. Pedrini, M., Massuda, R., de Lucena, D., Macedo, D., Paz, A.V., Lobato, M.I., Belmonte-de-Abreu, P.S., Cereser, K.M., Rocha, N.P., Curra, M.D., Panizzutti, B.S., Teixeira, A.L., Gama, C.S., Differences in eotaxin serum levels patients with recent onset and in chronic stable schizophrenia: a clue for understanding accelerating aging profile. Schizophr. Res. 152:2–3 (2014), 528–529.
49. Ramsey, J.M., Schwarz, E., Guest, P.C., van Beveren, N.J., Leweke, F.M., Rothermundt, M., Bogerts, B., Steiner, J., Bahn, S., Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One, 8(11), 2013, e78729.
50. Rapaport, M.H., Delrahim, K.K., Bresee, C.J., Maddux, R.E., Ahmadpour, O., Dolnak, D., Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry 57:12 (2005), 1594–1596.
51. Reale, M., Patruno, A., De Lutiis, M.A., Pesce, M., Felaco, M., Di Giannantonio, M., Di Nicola, M., Grilli, A., Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci., 12(1), 2011, 13.
52. Reaux-Le Goazigo, A., Van Steenwinckel, J., Rostene, W., Melik Parsadaniantz, S., Current status of chemokines in the adult CNS. Prog. Neurobiol. 104 (2013), 67–92.
53. Rezaie, P., Trillo-Pazos, G., Everall, I.P., Male, D.K., Expression of beta-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia 37:1 (2002), 64–75.
54. Schwartz, M., Shechter, R., Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurosci. 6:7 (2010), 405–410.
55. Schwarz, E., Guest, P.C., Rahmoune, H., Harris, L.W., Wang, L., Leweke, F., Rothermundt, M., Bogerts, B., Koethe, D., Kranaster, L., Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 17:5 (2012), 494–502.
56. Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Schizophrenia Working Group of the Psychiatric Genomics, C., Daly, M.J., Carroll, M.C., Stevens, B., McCarroll, S.A., Schizophrenia risk from complex variation of complement component 4. Nature 530:7589 (2016), 177–183.
57. Selvan, R.S., Kapadia, H.B., Platt, J.L., Complement-induced expression of chemokine genes in endothelium: regulation by IL-1-dependent and -independent mechanisms. J. Immunol. 161:8 (1998), 4388–4395.
58. Sorensen, T.L., Tani, M., Jensen, J., Pierce, V., Lucchinetti, C., Folcik, V.A., Qin, S., Rottman, J., Sellebjerg, F., Strieter, R.M., Frederiksen, J.L., Ransohoff, R.M., Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:6 (1999), 807–815.
59. Springer, T.A., Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:2 (1994), 301–314.
60. Stuart, M., Baune, B., Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci. Biobehav. Rev. 42 (2014), 93–115.
61. Stuart, M.J., Singhal, G., Baune, B.T., Systematic review of the neurobiological relevance of chemokines to psychiatric disorders. Front. Cell. Neurosci., 9, 2015, 357.
62. Sweileh, W.M., Odeh, J.B., Shraim, N.Y., Zyoud, S.H., Sawalha, A.F., Al-Jabi, S.W., Evaluation of defined daily dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm. J. 22:2 (2014), 127–132.
63. Teixeira, A.L., Reis, H.J., Nicolato, R., Brito-Melo, G., Correa, H., Teixeira, M.M., Romano-Silva, M.A., Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32:3 (2008), 710–714.
64. Villeda, S.A., Luo, J., Mosher, K.I., Zou, B., Britschgi, M., Bieri, G., Stan, T.M., Fainberg, N., Ding, Z., Eggel, A., Lucin, K.M., Czirr, E., Park, J.S., Couillard-Despres, S., Aigner, L., Li, G., Peskind, E.R., Kaye, J.A., Quinn, J.F., Galasko, D.R., Xie, X.S., Rando, T.A., Wyss-Coray, T., The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477:7362 (2011), 90–94.
65. Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care, 1992, 473–483.
66. Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B., Prediction of coronary heart disease using risk factor categories. Circulation 97:18 (1998), 1837–1847.
67. Wobrock, T., Ecker, U.K., Scherk, H., Schneider-Axmann, T., Falkai, P., Gruber, O., Cognitive impairment of executive function as a core symptom of schizophrenia. World J. Biol. Psychiatry, 2008, 1–10.
68. Xu, L., Kitade, H., Ni, Y., Ota, T., Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules 5:3 (2015), 1563–1579.
69. Zakharyan, R., Boyajyan, A., Arakelyan, A., Melkumova, M., Mrazek, F., Petrek, M., Monocyte chemoattractant protein-1 in schizophrenia: − 2518A/G genetic variant and protein levels in Armenian population. Cytokine 58:3 (2012), 351–354.
70. Zhang, X.Y., Zhou, D.F., Zhang, P.Y., Wu, G.Y., Cao, L.Y., Shen, Y.C., Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 57:2 (2002), 247–258.
71. Zlotnik, A., Yoshie, O., The chemokine superfamily revisited. Immunity 36:5 (2012), 705–716.